What is Galapagos NV (GLPG)?
Galapagos NV is a biotechnology company headquartered in Belgium, specializing in the discovery and development of small molecule medicines with novel modes of action. The company focuses on addressing diseases with significant unmet medical needs, including inflammatory, fibrotic, and other severe conditions. Galapagos operates a fully integrated drug discovery and development platform, combining proprietary technology with extensive expertise in genomics and medicinal chemistry. It collaborates with various pharmaceutical partners to advance its pipeline of therapeutic candidates through clinical development. The company’s research strategy emphasizes innovative approaches to target validation and drug design, aiming to create differentiated treatments. Galapagos maintains a global presence with research facilities and offices across Europe and the United States. Its organizational structure supports both internal programs and strategic partnerships, facilitating the translation of scientific discoveries into potential medicines. The company is recognized for its contributions to the biotechnology sector through its commitment to scientific innovation and collaborative development efforts.
Galapagos NV Stock Price Today: Live Overview
The price today is shaped by intraday trading, with Galapagos NV currently valued at €27.85. The price has moved between €27.55 and €28.35 during the session, with a daily percentage change of 0%.
FAQ: Galapagos NV (GLPG)
What is the current price of GLPG stock?
The stock price is currently €27.85.
Does GLPG pay dividends?
Galapagos NV pays dividends to its shareholders.
Does GLPG have a formal corporate presence or regional headquarters in the UAE?
Galapagos NV operates in the UAE via partnerships and distributors only.
What is GLPG best known for?
Galapagos NV is most famous for its biotechnology research and drug development.
What assets are typically shown together with GLPG?
Commonly shown alongside GLPG: Firefly Aerospace Inc., Inovio Pharmaceuticals, Citius Pharmaceuticals, Inc.
Latest shares articles



